---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-002832"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:39:47.291696+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports H1 net loss $4.5M, cash $9.1M; updates on EB613 and EB612 trials

## Summary
- H1 2023 net loss $4.5M ($0.16/share) vs $7.0M ($0.24) in H1 2022.
- Cash and equivalents $9.1M expected to fund operations into Q3 2024.
- R&D expenses $2.1M (down 32% YoY); G&A $2.4M (down 41% YoY).
- EB613 Phase 3 initiation depends on FDA review of FNIH-ASBMR SABRE BQP qualification.
- Phase 1B study of next-gen EB612 platform (45 subjects, 3 cohorts) started May 2023; H2 2023 data readout expected.

## SEC filing metadata
- accession: 0001178913-23-002832
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/0001178913-23-002832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/zk2330154.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-002832
- JSON: https://secwatch.observer/filing/0001178913-23-002832.json
- Plain text: https://secwatch.observer/filing/0001178913-23-002832.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported the six months ended June 30, 2023 results: net income Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, EPS $0.16 per ordinary share (basic and diluted).
  - Period: the six months ended June 30, 2023
  - Net income: Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023
  - EPS: $0.16 per ordinary share (basic and diluted)
  - Result: reported results
  source text: Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, as compared to $7.0 million, or $0.24 per ordinary share (basic and diluted), for the six months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/0001178913-23-002832-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.